Literature DB >> 32852718

Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice.

Pranglada Jearjaroen1, Kanet Pakdeepak1, Chainarong Tocharus2, Waraluck Chaichompoo3, Apichart Suksamrarn3, Jiraporn Tocharus4,5.   

Abstract

A high dose of dexamethasone induces neurodegeneration by initiating the inflammatory processes that lead to neural apoptosis. A dexamethasone administration model induces overproduction of amyloid-β (Aβ) and tau protein hyperphosphorylation and shows abnormalities of cholinergic function similar to Alzheimer's disease (AD). This study aimed to investigate the protective effect of hexahydrocurcumin on the brain of dexamethasone-induced mice. The results showed that hexahydrocurcumin and donepezil attenuated the levels of amyloid precursor protein and β-secretase mRNA by reverse transcription polymerase chain reaction, decreased the expression of hyperphosphorylated tau, and improved synaptic function. Moreover, we found that hexahydrocurcumin treatment could decrease interleukin-6 levels by attenuating p65 of nuclear factor kappa-light-chain-enhancer (NF-κB) of activated beta cells. In addition, hexahydrocurcumin also decreased oxidative stress, as demonstrated by the expression of 4-hydroxynonenal and thereby prevented apoptosis. Therefore, our finding suggests that hexahydrocurcumin prevents dexamethasone-induced AD-like pathology and improves memory impairment.

Entities:  

Keywords:  Alzheimer’s disease; Amyloidogenesis; Dexamethasone; Donepezil; Hexahydrocurcumin

Mesh:

Substances:

Year:  2020        PMID: 32852718     DOI: 10.1007/s12640-020-00269-y

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  45 in total

1.  Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.

Authors:  Kim N Green; Lauren M Billings; Benno Roozendaal; James L McGaugh; Frank M LaFerla
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

Review 2.  Clinical development of curcumin in neurodegenerative disease.

Authors:  Shuxin Hu; Panchanan Maiti; Qiulan Ma; Xiaohong Zuo; Mychica R Jones; Greg M Cole; Sally A Frautschy
Journal:  Expert Rev Neurother       Date:  2015-06       Impact factor: 4.618

3.  Chronic glucocorticoids exposure enhances neurodegeneration in the frontal cortex and hippocampus via NLRP-1 inflammasome activation in male mice.

Authors:  Wen Hu; Yaodong Zhang; Wenning Wu; Yanyan Yin; Dake Huang; Yuchan Wang; Weiping Li; Weizu Li
Journal:  Brain Behav Immun       Date:  2015-10-03       Impact factor: 7.217

4.  Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides.

Authors:  Krystyn Z Bourne; Diana C Ferrari; Christine Lange-Dohna; Steffen Rossner; Thomas G Wood; J Regino Perez-Polo
Journal:  J Neurosci Res       Date:  2007-05-01       Impact factor: 4.164

5.  Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.

Authors:  Chia-Hsiung Chen; Weihui Zhou; Shengchun Liu; Yu Deng; Fang Cai; Masahide Tone; Yukiko Tone; Yigang Tong; Weihong Song
Journal:  Int J Neuropsychopharmacol       Date:  2011-02-18       Impact factor: 5.176

Review 6.  Bioavailability of curcumin: problems and promises.

Authors:  Preetha Anand; Ajaikumar B Kunnumakkara; Robert A Newman; Bharat B Aggarwal
Journal:  Mol Pharm       Date:  2007-11-14       Impact factor: 4.939

7.  Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.

Authors:  Yasser Bustanji; Mutasem O Taha; Ihab M Almasri; Mohamed A S Al-Ghussein; Mohammad K Mohammad; Hatim S Alkhatib
Journal:  J Enzyme Inhib Med Chem       Date:  2009-06       Impact factor: 5.051

8.  NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42.

Authors:  Virginie Buggia-Prevot; Jean Sevalle; Steffen Rossner; Frédéric Checler
Journal:  J Biol Chem       Date:  2008-02-08       Impact factor: 5.157

9.  Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.

Authors:  Chatchawan Changtam; Harry P de Koning; Hasan Ibrahim; M Sohail Sajid; Matthew K Gould; Apichart Suksamrarn
Journal:  Eur J Med Chem       Date:  2009-11-24       Impact factor: 6.514

10.  Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer's Disease Rats Abrogating Aβ40/42 and Tau Hyperphosphorylation.

Authors:  Tushar Kanti Das; Piyali Jana; Swarup Kumar Chakrabarti; Mas R W Abdul Hamid
Journal:  J Alzheimers Dis Rep       Date:  2019-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.